A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

Eitemau Tebyg

• A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
  gan: Nathan, P, et al.
  Cyhoeddwyd: (2008)
• Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
  gan: Nathan, P, et al.
  Cyhoeddwyd: (2012)
• Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
  gan: Jane Lunt, S, et al.
  Cyhoeddwyd: (2011)
• The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
  gan: Prise, V, et al.
  Cyhoeddwyd: (2002)
• Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
  gan: Lunt, S, et al.
  Cyhoeddwyd: (2011)